Armand Butera

Guselkumab was effective in patients with previous biologic therapies, comorbidities or psoriasis manifestation in difficult-to-treat areas.

Despite being one of the most common dermatologic conditions, the etiology of chronic pruritis is still unknown, and conventional medication may not always result in a good therapeutic response.

A significant decrease in SII, SIRI, CRP, and UAS-7 was observed in the third month of omalizumab treatment, and the responder groups at 3 and 6 months of treatment had significantly higher baseline SII and SIRI levels than non-responders.

Dr. Trudzinski speaks of the importance of diagnosing sex-specific pulmonary and extra-pulmonary comorbidities in women with COPD, as well as the lack of research regarding COPD prevalence in women.

Safety and efficacy data for the oral asthma therapy was presented at a late-breaking session at ATS 2022.

Investigators defined AHR as “a hallmark of persistent asthma”, noting that it could also be assessed via indirect challenge with mannitol.

In particular, airway epithelial cells (AEC) in allergic asthmatic (AA) were shown to upregulate mucus metaplasia, matrix-remodeling, and glycolytic programs while failing to upregulate antioxidant genes.

Results from the 2 APPaRENT trials suggest regular inhaled corticosteroids/LABA alone or with short-acting beta agonists were the preferred treatment approach with physicians.

With this new decade-long cohort, Dr. Chen notes that researchers are "one step closer to a more accurate view of what sarcoidosis may be like in the United States", with has been suggested to be more prominent in African American communities.

A post-hoc analysis of the VOYAGE study also found that the biologic improved the percent predicted pre-bronchodilator FEV1 in this patient population.

Dr. Richmond speaks to the newest pulmonology data from Vanderbilt University that was presented at ATS 2022.

Dr. Chatterjee cites an urgent need for new treatment strategies, adding that reducing airway iron could result in a decrease in the production of aspergillus fumigatus proteases.

Dr. Au spoke of how the new data provides an opportunity to think about how lifestyle intervention focused on weight and moderate exercise can actually have meaningful impacts on patients with COPD.

This model was responsible for correctly identifying 73% of patients with pulmonary arterial hypertension 6 months prior to a confirmed diagnosis.

Dr. Holly Keir cites "massive changes" in beta diversity following ICS withdrawals in patients with moderate to very severe COPD.

Dr. Lugogo explains how the ProAir Digihaler was used to accurately monitor SABA use in patients with asthma -many of whom were overusing their medication- which could allow clinicians to make appropriate changes to treatment.

The new study provides insights into the physiological factors for greater AtoOxy efficacy and can be referenced when identifying patients who are most suited for the therapy.

Patients with a positive family history of OSA tended to be female with more severe OSA based on a higher AHI.

Obstructive sleep apnea has previously been associated with pulmonary hypertension in literature, with investigators citing a “complex and bidirectional relationship” between the 2 conditions.

Investigators from this ATS session suggested THN therapy could be used to treat OSA, believing in to be “a simpler approach than incumbent technology with no sensor and an easier, proximal electrode implantation”.

Dr. Rizzo sits down with HCPLive to discuss the impact of air pollution and allergies on pulmonary health, as well as new research on pulmonary arterial hypertension.

Research has indicated that a fixed-dose combination of albuterol and budesonide could better reduce the risk of severe asthma exacerbation when compared to albuterol alone.

Patients treated twice-daily with an 18 mg dose of BI 1015550 experienced prevention of decreased lung function regardless of any background antifibrotic agents.

Dr. Tara Vijayan speaks on improving COVID-19 treatment from “an equity standpoint, an ethical standpoint, and an evidence standpoint”.

These new data come as the FDA reviews the new drug application for deucravacitinib which, if approved, would make deucravacitinib the first allosteric tyrosine kinase 2 inhibitor approved for any disease.

The inflammatory markers and leukocyte profiles detailed in the study had not been previously evaluated in any longitudinal studies.

Despite this, an increased incidence of mild to moderate oral candidiasis was also observed in the pooled data from 8 trials.

The prevalence of sleep-disordered breathing differed across various etiologies of heart failure.

Previously, the US Preventive Services Task Force reviewed screening evidence for COPD in 2016 and issued a D recommendation against screening in asymptomatic adults.

Recent research has indicated that photos of skin can be used to assess AD severity.